NeuroVenti, Inc., is an innovative biotech startup company developing small molecule drugs against neurodevelopmental conditions, such as autism spectrum disorder (ASD) and syndromic ASD-like fragile X syndrome. Our pipeline includes multi-target drugs which can be applied for phase II clinical trials. We also provide CDRO (Clinical Development and Research Organization) services, including drug discovery, pre-clinical evaluation of efficacy and safety for candidate molecules targeting CNS (neurological, psychiatric, and neurodevelopmental) disorders. we aim to provide the customer-oriented and optimized evaluation services. Listen to your “Need”, “Bespoke” CDRO service, Until you say “Yes” !!